Biomerica (Nasdaq: BMRA) signed a three-year, auto-renewing CDMO Master Services Agreement with a confidential life sciences partner to develop proprietary IVD assays.
The engagement targets over $1.75 million in initial development fees, with milestone-based revenue, using Biomerica’s existing FDA-licensed, ISO 13485-certified Irvine facility and team.
Loading...
Loading translation...
Positive
Initial contract development target fee of over $1.75 million across multiple SOWs
Three-year Master Services Agreement with automatic one-year renewals
Milestone-based revenue recognition tied to accepted SOW deliverables
Work performed at FDA-licensed, ISO 13485-certified Irvine facility
Capital-light use of existing staff, equipment, and infrastructure
CDMO revenue stream alongside core inFoods IBS program
Negative
None.
News Market Reaction – BMRA
-1.02%
5 alerts
-1.02%Session close to close
+4.2%Peak Tracked
-11.5%Trough Tracked
$7.59MMarket Cap
0.7xRel. Volume
In the May 28 session, BMRA declined 1.02%, reflecting a mild negative market reaction.
Argus tracked a peak move of +4.2% during that session.
Argus tracked a trough of -11.5% from its starting point during tracking.
Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
This announcement outlines a CDMO Master Services Agreement with an initial development fee target o...
Analysis
This announcement outlines a CDMO Master Services Agreement with an initial development fee target of over $1.75 million, using Biomerica’s FDA-licensed, ISO 13485-certified facility and more than 40 years of ELISA expertise. It positions CDMO work as a capital-light, parallel revenue stream alongside inFoods IBS. Against prior 10-Q disclosures of net losses and going-concern doubts, investors may watch contract execution, milestone revenues, and continued reimbursement and commercialization progress as key metrics.
Q3 FY2026 results showing revenue decline but progress on margins and CDMO focus.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent BMRA news, mostly positive on commercialization and reimbursement, has produced modest single-digit price moves with one divergence on scientific conference data.
Recent Company History
Over the past months, BMRA highlighted several milestones: a Medicare billing pathway and $300 national payment rate for inFoods® IBS, a Canadian launch targeting up to 5 million patients, and third-quarter fiscal 2026 results emphasizing higher-margin diagnostics and CDMO services. Conference data acceptance and a separate management appointment event also featured. Today’s CDMO Master Services Agreement extends this commercialization and services narrative by adding contracted IVD development revenue on top of the inFoods® IBS focus.
Key Terms
cdmo, master services agreement, in vitro diagnostic, ivd, +2 more
6 terms
cdmofinancial
"reflecting the Company’s CDMO strategy as a capital-efficient, parallel revenue stream"
A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.
master services agreementfinancial
"today announced it has entered into a Master Services Agreement (MSA)"
A master services agreement is a standing contract that sets the main terms, responsibilities, pricing framework and processes for future work between two parties, allowing individual projects or orders to be added later without renegotiating core terms. For investors, it signals predictability and reduced legal friction around revenue streams and costs—like a subscription plan for services that makes future income and obligations easier to forecast and value.
in vitro diagnosticmedical
"to develop proprietary in vitro diagnostic (IVD) assays"
In vitro diagnostics are tests, instruments and kits used to analyze samples taken from the body—such as blood, urine or swabs—outside the body (in a lab or cartridge) to detect disease, infections, genetic traits or other biological signs. Investors care because these products generate sales, recurring revenue from consumable test kits, and value that hinges on test accuracy, regulatory approvals and reimbursement policies; like a home pregnancy test but for many medical conditions.
ivdmedical
"to develop proprietary in vitro diagnostic (IVD) assays"
IVD stands for in vitro diagnostic — tests, instruments and kits that analyze samples taken from the body (blood, saliva, tissue) outside the body, such as lab assays or home pregnancy tests. Investors watch IVDs because they drive recurring sales, depend on regulatory approval and insurance coverage to reach markets, and differences in accuracy, cost or availability can quickly affect a maker’s revenue and legal risk.
elisamedical
"expression of the same ELISA-based assay development expertise that underpins Biomerica’s own"
A laboratory test that detects specific proteins or antibodies in a sample by producing a measurable color or signal, similar to how a home pregnancy test shows a line when it finds a target substance. Investors care because ELISA results help determine whether a medical product works, meets regulatory standards, or can be manufactured reliably — factors that affect a company’s revenue potential, approval timelines, and risk profile.
iso 13485regulatory
"Biomerica’s FDA-licensed, ISO 13485-certified facility in Irvine, California"
ISO 13485 is an international quality management standard for organizations that design, produce, or service medical devices. Think of it as a factory’s rulebook and checklist that helps ensure products are safe, consistently made, and meet regulatory rules worldwide. For investors, certification signals lower operational and regulatory risk, easier market access, and greater reliability of a company’s medical products and supply chain — similar to buying from a trusted, inspected supplier.
Auto-renewing Master Services Agreement engages Biomerica’s integrated development and manufacturing platform, reflecting the Company’s CDMO strategy as a capital-efficient, parallel revenue stream alongside its core inFoods® IBS program
IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a developer and manufacturer of diagnostic test systems and CDMO services provider, today announced it has entered into a Master Services Agreement (MSA) with a confidential life sciences company to develop proprietary in vitro diagnostic (IVD) assays. The engagement carries an initial contract development target fee of over $1.75 million, to be earned across multiple Statements of Work (SOWs) under the MSA. Biomerica was chosen following a competitive evaluation in which multiple CDMO organizations were assessed.
The MSA establishes an initial three-year term with automatic one-year renewals. All development work will be performed at Biomerica’s FDA-licensed, ISO 13485-certified facility in Irvine, California. Revenue will be recognized on a milestone-completion basis as individual SOW deliverables are accepted.
CDMO STRATEGY AND REVENUE CONTEXT
This CDMO engagement is a direct expression of the same ELISA-based assay development expertise that underpins Biomerica’s own inFoods® IBS technology platform — using capabilities built and refined over more than 40 years. The Company is not pivoting from its core focus; rather, it is monetizing its established infrastructure and scientific capabilities in a capital-efficient, parallel revenue stream. inFoods® IBS remains Biomerica’s primary commercial priority.
The development work is designed to be completed by Biomerica’s existing team of research scientists using the Company’s existing equipment and infrastructure. This capital-light structure is expected to require minimal incremental costs, creating meaningful operating leverage as the CDMO program scales.
MANAGEMENT COMMENTARY
“Biomerica’s primary mission remains the commercialization of inFoods® IBS — a clinically validated, precision diagnostic that we believe has the potential to transform how IBS is managed for millions of patients. At the same time, the scientific infrastructure, regulatory expertise, and ELISA development capabilities we have built to bring inFoods to market are now generating direct revenue through our CDMO business.
The $1.75 million in initial development fees provides near-term revenue visibility and demonstrates that the capabilities Biomerica has built over more than 40 years — in assay development, regulatory compliance, and IVD manufacturing — have direct commercial value beyond our own product pipeline.”
— Zack Irani, Chief Executive Officer, Biomerica, Inc.
The identity of the partner organization is not being disclosed at this time pursuant to confidentiality obligations.
ABOUT BIOMERICA, INC.
Biomerica, Inc. (Nasdaq: BMRA) is a global biomedical technology company that develops, manufactures, and markets diagnostic test systems and provides integrated CDMO services for the healthcare market. The Company specializes in immunoassay-based technologies, including ELISA and lateral flow platforms, with more than 40 years of expertise in assay development, manufacturing, and regulatory compliance. Biomerica holds ISO 13485 certification, is registered with the U.S. Food and Drug Administration, and has supported regulatory submissions in multiple jurisdictions including FDA 510(k) clearances and EU IVDR registrations. The Company’s flagship inFoods® IBS product is a precision diagnostic-guided therapy validated in a landmark multicenter clinical trial published in Gastroenterology. For more information, visit www.biomerica.com and www.inFoodsIBS.com.
INVESTOR RELATIONS CONTACT
Biomerica, Inc. │ 17571 Von Karman Ave, Irvine, CA 92614 investors@biomerica.com │ (949) 645-2111 │ www.biomerica.com
Safe Harbor Statement
Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the target contract development fee of approximately $1.75 million, expectations regarding SOW execution, milestone completion, and program timelines, and the Company’s expectations regarding its CDMO business as a revenue stream. The $1.75 million aggregate estimate is across multiple SOWs that have not all been executed; no revenue is recognized absent an executed SOW and accepted milestone deliverables. Actual results may differ materially due to SOW non-execution, program cancellation, MSA termination, and other risks described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Biomerica undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.
Source: Biomerica, Inc.
FAQ
What did Biomerica (NASDAQ: BMRA) announce on May 28, 2026 about its CDMO business?
Biomerica announced a CDMO Master Services Agreement to develop proprietary IVD assays with a confidential life sciences company. According to Biomerica, the agreement targets over $1.75 million in initial development fees, supporting its strategy of a capital-efficient, parallel revenue stream.
How much is the Biomerica (BMRA) CDMO Master Services Agreement potentially worth?
The CDMO Master Services Agreement carries an initial contract development target fee of over $1.75 million. According to Biomerica, this amount will be earned across multiple Statements of Work, with revenue recognized on a milestone-completion basis as individual deliverables are accepted.
What is the term of Biomerica’s new CDMO Master Services Agreement and renewal structure?
The CDMO Master Services Agreement has an initial three-year term with automatic one-year renewals. According to Biomerica, this structure can provide ongoing CDMO revenue opportunities, assuming future Statements of Work and continued collaboration with the confidential life sciences partner.
Where will Biomerica (BMRA) perform the IVD assay development work under this CDMO agreement?
All development work will be performed at Biomerica’s FDA-licensed, ISO 13485-certified facility in Irvine, California. According to Biomerica, existing research scientists, equipment, and infrastructure will be used, supporting a capital-light structure with minimal expected incremental costs as the CDMO program scales.
How does the new CDMO Master Services Agreement align with Biomerica’s inFoods IBS strategy?
The CDMO engagement uses the same ELISA-based assay expertise behind Biomerica’s inFoods IBS platform. According to Biomerica, CDMO services are a parallel, capital-efficient revenue stream, while inFoods IBS remains the company’s primary commercial priority and core strategic focus.
How will Biomerica recognize revenue from the $1.75 million CDMO Master Services Agreement?
Biomerica will recognize CDMO revenue on a milestone-completion basis as individual Statements of Work deliverables are accepted. According to Biomerica, this approach ties revenue timing directly to project progress and accepted milestones under the Master Services Agreement.
Why was Biomerica selected for this IVD CDMO Master Services Agreement?
Biomerica was chosen following a competitive evaluation of multiple CDMO organizations. According to Biomerica, the decision reflects its ELISA-based assay development experience, regulatory expertise, and over 40 years of work in assay development, regulatory compliance, and IVD manufacturing capabilities.
